Drug intelligence / Profile preview

anti-HER-2004 + hepatitis B surface antigen

Development stage: Preclinical
Lead developer: Phoenix Biomolecular Engineering Foundation
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Antibody-Based Therapeutics
Administration: Intravenous

Overview

anti-HER-2004 + hepatitis B surface antigen is an Antibody-Vaccine Engineered Construct (AVEC) designed for the treatment of HER2-positive cancers, particularly ovarian epithelial cancer. Developed by Marek Malecki and the Pharma-Biotech-Medical-Ethical Foundation (PBMEF), the drug consists of a monoclonal antibody (clone anti-HER-2004) targeting the Human Epidermal Growth Factor Receptor 2 (HER2) conjugated to the Hepatitis B surface antigen (HBsAg) virus-like particle (VLP). The therapeutic strategy, termed Redirected, Accelerated, Amplified, Vaccination-Induced Immunotherapy (RAAVIIT), leverages the patient's existing immunity from prior Hepatitis B vaccinations. By anchoring to HER2 on tumor cells, the construct displays HBsAg, which acts as a target for circulating anti-HBsAg antibodies. This recruitment of the adaptive and innate immune systems triggers potent antibody-dependent cell cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), resulting in enhanced tumor cell eradication compared to naked anti-HER2 antibodies.

Other names: AVECAntibody x Vaccine Engineered Construct

Targets

C1Q (Complement C1q)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)ERBB2 (Erb-b2 receptor tyrosine kinase 2)HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on anti-HER-2004 + hepatitis B surface antigen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-HER-2004 + hepatitis B surface antigen.